EUCTR2007-002143-25-GB进行中（未招募）1 期
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Chronic or relapsed Chronic Lymphocytic Leukemia and require treatment in the opinion of the investigator.
- •2. Eastern Cooperative Oncology Group (ECOG) performance score of = 1.
- •3. Adequate bone marrow independent of growth factor support, renal and hepatic function per defined laboratory criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has a history or is significantly suspicious for cancer related Central Nervous System (CNS) disease.
- •2. Receipt of allogenic or autologous stem cell transplant.
- •3. Recent history (within 1 year of first dose) of underlying, predisposing condition of bleeding or currently
- •exhibit signs of bleeding.
- •4. Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.
- •5. Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within 1 year
- •of first dose).
研究者
相似试验
进行中（未招募）
不适用
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.Relapsed or Refractory Chronic Lymphocytic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractoryMedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2007-002143-25-DEAbbott GmbH & Co. KG72
进行中（未招募）
不适用
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only).MedDRA version: 8.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-003298-28-GBAbbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England)90
招募中
1 期
(VELA) Study of BLU-222 in Advanced Solid TumorsHR+ Breast CancerCCNE1 AmplificationHER2-negative Breast CancerAdvanced Solid TumorOvarian CancerEndometrial CancerGastric CancerMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2022-502528-29-00Blueprint Medicines Corp.366
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerPancreatic Ductal AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2018-001028-21-ESMedImmune, LLC204
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerEUCTR2018-001028-21-NOMedImmune, LLC195